Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
09:00am, Monday, 17'th Jun 2024
Eli Lilly has more work it wants to do with the hard-won success from its weight loss and diabetes drugs, Zepbound and Mounjaro, outgoing CFO Anat Ashkenazi told CNBC. The company is working to ramp u
GLP-1 weight-loss drugs: Analyst discusses what investors should know
02:28pm, Friday, 14'th Jun 2024
GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter join
Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts
07:28pm, Thursday, 13'th Jun 2024
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk GLP-1 drug competition, its liver disease treatment, its Mash drug rollout and more.
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today ann
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
10:16am, Wednesday, 12'th Jun 2024
Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain aft
Structure Therapeutics CEO on GLP drugs
06:37pm, Tuesday, 11'th Jun 2024
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to discuss the weight loss drug boom and the company's recent data finidngs in its own drug.
The Vitamin Shoppe CEO on GLP-1 drugs
11:42am, Tuesday, 11'th Jun 2024
The Vitamin Shoppe CEO Lee Wright joins 'Squawk on the Street' to discuss what the chief executive has learned about GLP-1 drugs, if science says GLP-1 users should supplement their diet with proteins
Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study
09:00am, Wednesday, 05'th Jun 2024
Second study arm dosing is now complete. KELOWNA, BC / ACCESSWIRE / June 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug deliver
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
07:42am, Monday, 03'rd Jun 2024
Him & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand an
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
08:25am, Sunday, 02'nd Jun 2024
The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications,
Nutritional needs for users of GLP-1 drugs are 'shifting', Nestle CEO says
11:35am, Thursday, 30'th May 2024
Nestle CEO Mark Schneider discusses the impact of GLP-1 drugs on the food industry and the company's products that are tailored to users of the drugs.
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
11:32am, Tuesday, 28'th May 2024
As weight loss drugs are gaining popularity a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everythin
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its le
How digital health companies are capitalizing on the GLP-1 boom
09:00am, Saturday, 25'th May 2024
Some analysts estimate that anti-obesity medications could grow into a $100 billion industry by the end of the decade. Companies including Calibrate, Ro and WeightWatchers are looking to capitalize on
